Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 01/27/2014 -- Reportstack, provider of premium market research reports announces the addition of Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013 market report to its offering
Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013


, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Allergic Rhino-Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis.
- A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

BioTech Tools
ALK-Abello A/S
Allergy Therapeutics plc
Stallergenes S.A.
Cytos Biotechnology AG
Allergopharma Joachim Ganzer KG
Greer Laboratories, Inc.
Laboratorios LETI S.L.
Immunomic Therapeutics, Inc.
Bial - Portela & Ca, S.A.
Roxall Medizin GmbH

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604